D Li1, Y Chen, W Zhang, S Zheng, Q Zhang, C Bai, P Zhang. 1. Key Laboratory of Cancer Prevention and Therapy, Department of Clinical Laboratory, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, People's Republic of China, lidingly@126.com.
Abstract
BACKGROUND: Incidence of infection due to extended-spectrum β-lactamase producing Klebsiella pneumoniae (ESBL-KP) has increased rapidly in recent years. However, its prevalence in cancer patients is seldom reported. AIMS: This study was designed to identify the risk factors for bloodstream infections (BSIs) with ESBL-KP, and to understand its susceptibility among cancer patients on antibiotics. METHODS: We conducted a retrospective study with a total of 118 cancer patients between 2009 and 2011 with BSIs, among which 88 were infected with non-ESBL-KP and 30 with ESBL-KP. Patterns of susceptibility, clinical characteristics and mortality were investigated. Multivariate logistic regression model was used to unveil independent risk factors. RESULTS: On multivariate analysis, length of stay (LOS) (p = 0.025), and prior exposure to cephalosporins (p = 0.006), fluoroquinolones (p = 0.011), macrolides (p = 0.007) and aminoglycosides (p = 0.008) were independent risk factors for BSIs of ESBL-KP. For mortality, there was no significant difference between ESBL-KP and non-ESBL-KP groups (p = 0.431). Moreover, compared with non-ESBL-KP, ESBL-KP displayed reduced sensitivity to aminoglycosides (p < 0.001, except amikacin), fluoroquinolones (p < 0.001), piperacillin-tazobactam (p = 0.005) and trimethoprim-sulfamethoxazole (p < 0.001), respectively. CONCLUSIONS: ESBL-KP exhibited less susceptibility to various non-β-lactamase antibiotics, and infections due to these organisms were related to LOS and preexisting use of antibiotics. Thus, judicious use of all antibiotics should be underscored to reduce the infections caused by ESBL-KP.
BACKGROUND: Incidence of infection due to extended-spectrum β-lactamase producing Klebsiella pneumoniae (ESBL-KP) has increased rapidly in recent years. However, its prevalence in cancerpatients is seldom reported. AIMS: This study was designed to identify the risk factors for bloodstream infections (BSIs) with ESBL-KP, and to understand its susceptibility among cancerpatients on antibiotics. METHODS: We conducted a retrospective study with a total of 118 cancerpatients between 2009 and 2011 with BSIs, among which 88 were infected with non-ESBL-KP and 30 with ESBL-KP. Patterns of susceptibility, clinical characteristics and mortality were investigated. Multivariate logistic regression model was used to unveil independent risk factors. RESULTS: On multivariate analysis, length of stay (LOS) (p = 0.025), and prior exposure to cephalosporins (p = 0.006), fluoroquinolones (p = 0.011), macrolides (p = 0.007) and aminoglycosides (p = 0.008) were independent risk factors for BSIs of ESBL-KP. For mortality, there was no significant difference between ESBL-KP and non-ESBL-KP groups (p = 0.431). Moreover, compared with non-ESBL-KP, ESBL-KP displayed reduced sensitivity to aminoglycosides (p < 0.001, except amikacin), fluoroquinolones (p < 0.001), piperacillin-tazobactam (p = 0.005) and trimethoprim-sulfamethoxazole (p < 0.001), respectively. CONCLUSIONS: ESBL-KP exhibited less susceptibility to various non-β-lactamase antibiotics, and infections due to these organisms were related to LOS and preexisting use of antibiotics. Thus, judicious use of all antibiotics should be underscored to reduce the infections caused by ESBL-KP.
Authors: Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Rafael Cantón; Fernando Baquero Journal: Antimicrob Agents Chemother Date: 2010-04-26 Impact factor: 5.191
Authors: Victor D Rosenthal; Hu Bijie; Dennis G Maki; Yatin Mehta; Anucha Apisarnthanarak; Eduardo A Medeiros; Hakan Leblebicioglu; Dale Fisher; Carlos Álvarez-Moreno; Ilham Abu Khader; Marisela Del Rocío González Martínez; Luis E Cuellar; Josephine Anne Navoa-Ng; Rédouane Abouqal; Humberto Guanche Garcell; Zan Mitrev; María Catalina Pirez García; Asma Hamdi; Lourdes Dueñas; Elsie Cancel; Vaidotas Gurskis; Ossama Rasslan; Altaf Ahmed; Souha S Kanj; Olber Chavarría Ugalde; Trudell Mapp; Lul Raka; Cheong Yuet Meng; Le Thi Anh Thu; Sameeh Ghazal; Achilleas Gikas; Leonardo Pazmiño Narváez; Nepomuceno Mejía; Nassya Hadjieva; May Osman Gamar Elanbya; María Eugenia Guzmán Siritt; Kushlani Jayatilleke Journal: Am J Infect Control Date: 2011-09-10 Impact factor: 2.918
Authors: David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu Journal: Clin Infect Dis Date: 2004-06-08 Impact factor: 9.079
Authors: Guillermo V Sanchez; Ronald N Master; Richard B Clark; Madiha Fyyaz; Padmaraj Duvvuri; Gupta Ekta; Jose Bordon Journal: Emerg Infect Dis Date: 2013-01 Impact factor: 6.883